ConductScience.org, home
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
API referenceFor AI assistants

Trial · NCT01989754

Adverse events1,294

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,294

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherBalanoposthitisReproductive system and breast disordersPlacebo (Placebo)252,903
otherBalanoposthitisReproductive system and breast disordersCanagliflozin (Experimental)942,904
seriousAnaemiaBlood and lymphatic system disordersPlacebo (Placebo)62,903
seriousAnaemiaBlood and lymphatic system disordersCanagliflozin (Experimental)102,904
seriousFebrile NeutropeniaBlood and lymphatic system disordersPlacebo (Placebo)12,903
seriousFebrile NeutropeniaBlood and lymphatic system disordersCanagliflozin (Experimental)02,904
seriousIron Deficiency AnaemiaBlood and lymphatic system disordersPlacebo (Placebo)22,903
seriousIron Deficiency AnaemiaBlood and lymphatic system disordersCanagliflozin (Experimental)12,904
seriousPolycythaemiaBlood and lymphatic system disordersPlacebo (Placebo)02,903
seriousPolycythaemiaBlood and lymphatic system disordersCanagliflozin (Experimental)12,904
seriousThrombocytopeniaBlood and lymphatic system disordersPlacebo (Placebo)12,903
seriousThrombocytopeniaBlood and lymphatic system disordersCanagliflozin (Experimental)02,904
seriousAcute Coronary SyndromeCardiac disordersPlacebo (Placebo)112,903
seriousAcute Coronary SyndromeCardiac disordersCanagliflozin (Experimental)42,904
seriousAcute Left Ventricular FailureCardiac disordersPlacebo (Placebo)12,903
seriousAcute Left Ventricular FailureCardiac disordersCanagliflozin (Experimental)12,904
seriousAcute Myocardial InfarctionCardiac disordersPlacebo (Placebo)262,903
seriousAcute Myocardial InfarctionCardiac disordersCanagliflozin (Experimental)322,904
seriousAdams-Stokes SyndromeCardiac disordersPlacebo (Placebo)02,903
seriousAdams-Stokes SyndromeCardiac disordersCanagliflozin (Experimental)12,904

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01989754/events

API referenceFor AI assistants